Abstract:Background: Within the field of oncotherapy, research interest regarding immunotherapy has risen to the point that it is now seen as a key application. However, inherent disadvantages of immune checkpoint inhibitors (ICIs), such as their low response rates and immune-related adverse events (irAEs), currently restrict their clinical application. Were these disadvantages to be overcome, more patients could derive prolonged benefits from ICIs. At present, many basic experiments and clinical studies using hyperthermia combined with ICI treatment (HIT) have been performed and shown the potential to address the above challenges. Therefore, this review extensively summarizes the knowledge and progress of HIT for analysis and discusses the effect and feasibility. Methods: In this review, we explored the PubMed and clinicaltrials.gov databases, with regard to the searching terms "immune checkpoint inhibitor, immunotherapy, hyperthermia, ablation, photothermal therapy". Results: By reviewing the literature, we analyzed how hyperthermia influences tumor immunology and improves the efficacy of ICI. Hyperthermia can trigger a series of multifactorial molecular cascade reactions between tumors and immunization and can significantly induce cytological modifications within the tumor microenvironment (TME). The pharmacological potency of ICIs can be enhanced greatly through the immunomodulatory amelioration of immunosuppression, and the activation of immunostimulation. Emerging clinical trials outcome regarding HIT have verified and enriched the theoretical foundation of synergistic sensitization. Conclusion: HIT research is now starting to transition from preclinical studies to clinical investigations. Several HIT sensitization mechanisms have been reflected and demonstrated as significant survival benefits for patients through pioneering clinical trials. Further studies into the theoretical basis and practical standards of HIT, combined with larger-scale clinical studies involving more cancer types, will be necessary for the future.

Synergistic Antitumor Effect of Cxcl10 with Hyperthermia

Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy

Improved Therapeutic Effectiveness By Combining Recombinant Cxc Chemokine Ligand 10 With Cisplatin In Solid Tumors

Hyperthermia Synergizes with Tissue Factor Knockdown to Suppress the Growth and Hepatic Metastasis of Colorectal Cancer in Orthotopic Tumor Model.

Hyperthermia Increases the Therapeutic Efficacy of Survivint34a in Mouse Tumor Models

Antitumor Efficacy of Combination of Interferon-Gamma-inducible Protein 10 Gene with Gemcitabine, a Study in Murine Model

[Antitumor Effects of Interferon-Gamma-inducible Protein 10 Combined with Gemcitabine].

Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors

Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors

Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy

The Enhanced Anti-Angiogenic and Antitumor Effects of Combining Flk1-Based Dna Vaccine and Ip-10

CXCL10-coronated Thermosensitive "stealth" Liposomes for Sequential Chemoimmunotherapy in Melanoma.

The CXCL10/CXCR3 Pathway Contributes to the Synergy of Thermal Ablation and PD-1 Blockade Therapy against Tumors

IP10 enhances anti-tumor immunity and its mechanisms

Progress of Combination Therapy for Tumor Comprising Hyperthermia with Dendritic Cells

Intracellular Magnetic Hyperthermia Enables Concurrent Down-Regulation of CD47 and SIRPα to Potentiate Antitumor Immunity.

Targeted in Vivo Expression of IFN-gamma-inducible Protein 10 Induces Specific Antitumor Activity.

The role of hyperthermia in the treatment of tumor

Enhanced Tumor Synergistic Therapy by Injectable Magnetic Hydrogel Mediated Generation of Hyperthermia and Highly Toxic Reactive Oxygen Species.

Effective Antitumor Synergistic Treatment with Fiber-Photothermal Therapy and Heat Shock Protein Inhibitors